v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by the CODM are reported on the condensed consolidated statements of earnings for the periods ended March 31, 2026 and 2025. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.
The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)20262025
Immunology
SkyriziUnited States$3,775 $2,919 
International708 506 
Total$4,483 $3,425 
RinvoqUnited States$1,405 $1,220 
International714 498 
Total$2,119 $1,718 
HumiraUnited States$357 $744 
International331 377 
Total$688 $1,121 
Neuroscience
VraylarUnited States$902 $763 
International3 2 
Total$905 $765 
Botox TherapeuticUnited States$842 $723 
International167 143 
Total$1,009 $866 
UbrelvyUnited States$330 $233 
International9 7 
Total$339 $240 
QuliptaUnited States$250 $172 
International46 21 
Total$296 $193 
VyalevUnited States$89 $6 
International112 57 
Total$201 $63 
Other NeuroscienceUnited States$46 $75 
International79 80 
Total$125 $155 
Oncology
VenclextaUnited States$341 $312 
International429 353 
Total$770 $665 
Three months ended
March 31,
(in millions)20262025
ImbruvicaUnited States$332 $529 
Collaboration revenues224 209 
Total$556 $738 
Elahere
United States
$160 $165 
International
38 14 
Total$198 $179 
Epkinly
Collaboration revenues
$51 $36 
International32 15 
Total$83 $51 
Other OncologyUnited States$24 $— 
Aesthetics
Botox CosmeticUnited States$371 $295 
International297 261 
Total$668 $556 
Juvederm CollectionUnited States$85 $75 
International147 156 
Total$232 $231 
Other AestheticsUnited States$248 $270 
International38 45 
Total$286 $315 
Other Key Products
MavyretUnited States$183 $142 
International168 164 
Total$351 $306 
CreonUnited States$361 $355 
Linzess
United States$272 $139 
International11 9 
Total$283 $148 
All other$1,025 $1,253 
Total net revenues$15,002 $13,343 
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 7), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 11) and income tax expense (Note 10).